Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood th1/th2 cell ratios

Koji Nakagawa, Joanne Kwak-Kim, Kuniaki Ota, Keiji Kuroda, Michi Hisano, Rikikazu Sugiyama, Koushi Yamaguchi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Problem: We evaluated the clinical efficacy of immunosuppressive treatment with tacrolimus for repeated implantation failure (RIF) patients who have elevated in T helper (Th1)/Th2 cytokine producing cell ratios. Method of study: This was a prospective cohort study of treatment for RIF patients (n = 42) with elevated peripheral blood Th1 (CD4+/IFN-γ+)/Th2 (CD4+/IL-4+) cell ratios at the Sugiyama clinic between November 2011 and October 2013. Twenty-five patients were treated with tacrolimus (treatment group) and 17 received no treatment (control group). Treatment group received tacrolimus 2 days before embryo transfer and continued until the day of the pregnancy test, for a total of 16 days. The daily dose of tacrolimus (1-3 mg) was determined based on the degree of the Th1/Th2 cell ratio. Results: The clinical pregnancy rate of the treatment group was 64.0%, which was significantly higher than that of the control group (0%) (P < 0.0001). In the treatment group, the miscarriage rate was 6.3%, the live birthrate was 60.0% (P < 0.0001). There was no significant side-effect from tacrolimus in treatment group. No one developed obstetrical complications during pregnancy. Conclusion: An immunosuppressive treatment using tacrolimus improved pregnancy outcome of repeated implantation failure patients with elevated Th1/Th2 ratios.

Original languageEnglish
Pages (from-to)353-361
Number of pages9
JournalAmerican Journal of Reproductive Immunology
Volume73
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Th2 Cells
Th1 Cells
Tacrolimus
Immunosuppression
Blood Cells
Therapeutics
Immunosuppressive Agents
Pregnancy Tests
Control Groups
Pregnancy Complications
Embryo Transfer
Spontaneous Abortion
Pregnancy Rate
Pregnancy Outcome
Interleukin-4
Cohort Studies
Prospective Studies
Cytokines

Keywords

  • IVF
  • Repeated implantation failure
  • Tacrolimus
  • Th1/Th2 ratios

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood th1/th2 cell ratios. / Nakagawa, Koji; Kwak-Kim, Joanne; Ota, Kuniaki; Kuroda, Keiji; Hisano, Michi; Sugiyama, Rikikazu; Yamaguchi, Koushi.

In: American Journal of Reproductive Immunology, Vol. 73, No. 4, 01.04.2015, p. 353-361.

Research output: Contribution to journalArticle

Nakagawa, Koji ; Kwak-Kim, Joanne ; Ota, Kuniaki ; Kuroda, Keiji ; Hisano, Michi ; Sugiyama, Rikikazu ; Yamaguchi, Koushi. / Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood th1/th2 cell ratios. In: American Journal of Reproductive Immunology. 2015 ; Vol. 73, No. 4. pp. 353-361.
@article{c4e6b4a015a24942b0c46994645c9ee9,
title = "Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood th1/th2 cell ratios",
abstract = "Problem: We evaluated the clinical efficacy of immunosuppressive treatment with tacrolimus for repeated implantation failure (RIF) patients who have elevated in T helper (Th1)/Th2 cytokine producing cell ratios. Method of study: This was a prospective cohort study of treatment for RIF patients (n = 42) with elevated peripheral blood Th1 (CD4+/IFN-γ+)/Th2 (CD4+/IL-4+) cell ratios at the Sugiyama clinic between November 2011 and October 2013. Twenty-five patients were treated with tacrolimus (treatment group) and 17 received no treatment (control group). Treatment group received tacrolimus 2 days before embryo transfer and continued until the day of the pregnancy test, for a total of 16 days. The daily dose of tacrolimus (1-3 mg) was determined based on the degree of the Th1/Th2 cell ratio. Results: The clinical pregnancy rate of the treatment group was 64.0{\%}, which was significantly higher than that of the control group (0{\%}) (P < 0.0001). In the treatment group, the miscarriage rate was 6.3{\%}, the live birthrate was 60.0{\%} (P < 0.0001). There was no significant side-effect from tacrolimus in treatment group. No one developed obstetrical complications during pregnancy. Conclusion: An immunosuppressive treatment using tacrolimus improved pregnancy outcome of repeated implantation failure patients with elevated Th1/Th2 ratios.",
keywords = "IVF, Repeated implantation failure, Tacrolimus, Th1/Th2 ratios",
author = "Koji Nakagawa and Joanne Kwak-Kim and Kuniaki Ota and Keiji Kuroda and Michi Hisano and Rikikazu Sugiyama and Koushi Yamaguchi",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/aji.12338",
language = "English",
volume = "73",
pages = "353--361",
journal = "American Journal of Reproductive Immunology and Microbiology",
issn = "8755-8920",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood th1/th2 cell ratios

AU - Nakagawa, Koji

AU - Kwak-Kim, Joanne

AU - Ota, Kuniaki

AU - Kuroda, Keiji

AU - Hisano, Michi

AU - Sugiyama, Rikikazu

AU - Yamaguchi, Koushi

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Problem: We evaluated the clinical efficacy of immunosuppressive treatment with tacrolimus for repeated implantation failure (RIF) patients who have elevated in T helper (Th1)/Th2 cytokine producing cell ratios. Method of study: This was a prospective cohort study of treatment for RIF patients (n = 42) with elevated peripheral blood Th1 (CD4+/IFN-γ+)/Th2 (CD4+/IL-4+) cell ratios at the Sugiyama clinic between November 2011 and October 2013. Twenty-five patients were treated with tacrolimus (treatment group) and 17 received no treatment (control group). Treatment group received tacrolimus 2 days before embryo transfer and continued until the day of the pregnancy test, for a total of 16 days. The daily dose of tacrolimus (1-3 mg) was determined based on the degree of the Th1/Th2 cell ratio. Results: The clinical pregnancy rate of the treatment group was 64.0%, which was significantly higher than that of the control group (0%) (P < 0.0001). In the treatment group, the miscarriage rate was 6.3%, the live birthrate was 60.0% (P < 0.0001). There was no significant side-effect from tacrolimus in treatment group. No one developed obstetrical complications during pregnancy. Conclusion: An immunosuppressive treatment using tacrolimus improved pregnancy outcome of repeated implantation failure patients with elevated Th1/Th2 ratios.

AB - Problem: We evaluated the clinical efficacy of immunosuppressive treatment with tacrolimus for repeated implantation failure (RIF) patients who have elevated in T helper (Th1)/Th2 cytokine producing cell ratios. Method of study: This was a prospective cohort study of treatment for RIF patients (n = 42) with elevated peripheral blood Th1 (CD4+/IFN-γ+)/Th2 (CD4+/IL-4+) cell ratios at the Sugiyama clinic between November 2011 and October 2013. Twenty-five patients were treated with tacrolimus (treatment group) and 17 received no treatment (control group). Treatment group received tacrolimus 2 days before embryo transfer and continued until the day of the pregnancy test, for a total of 16 days. The daily dose of tacrolimus (1-3 mg) was determined based on the degree of the Th1/Th2 cell ratio. Results: The clinical pregnancy rate of the treatment group was 64.0%, which was significantly higher than that of the control group (0%) (P < 0.0001). In the treatment group, the miscarriage rate was 6.3%, the live birthrate was 60.0% (P < 0.0001). There was no significant side-effect from tacrolimus in treatment group. No one developed obstetrical complications during pregnancy. Conclusion: An immunosuppressive treatment using tacrolimus improved pregnancy outcome of repeated implantation failure patients with elevated Th1/Th2 ratios.

KW - IVF

KW - Repeated implantation failure

KW - Tacrolimus

KW - Th1/Th2 ratios

UR - http://www.scopus.com/inward/record.url?scp=84924408927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924408927&partnerID=8YFLogxK

U2 - 10.1111/aji.12338

DO - 10.1111/aji.12338

M3 - Article

AN - SCOPUS:84924408927

VL - 73

SP - 353

EP - 361

JO - American Journal of Reproductive Immunology and Microbiology

JF - American Journal of Reproductive Immunology and Microbiology

SN - 8755-8920

IS - 4

ER -